Figure 3.

The effect of PKCα expression on survival. Patients were divided into 2 groups, low and high, according to whether they were above or below the median PKCα expression observed in all 226 samples in 188 patients. Patients with a PKCα greater than the median level (P = .02) or in the highest third (P = .016) or the highest one sixth (P < .001) of this group had an inferior survival duration compared with those with levels of PKCα below the median, suggesting a progressively adverse prognostic effect of increasingly higher levels of PKCα.